These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

827 related items for PubMed ID: 30559184

  • 21. Effects of subanesthetic ketamine and (2R,6R) hydroxynorketamine on working memory and synaptic transmission in the nucleus reuniens in mice.
    Goswamee P, Rice R, Leggett E, Zhang F, Manicka S, Porter JH, McQuiston AR.
    Neuropharmacology; 2022 May 01; 208():108965. PubMed ID: 35065945
    [Abstract] [Full Text] [Related]

  • 22. Ketamine metabolite (2R,6R)-hydroxynorketamine enhances aggression via periaqueductal gray glutamatergic transmission.
    Ye L, Ko CY, Huang Y, Zheng C, Zheng Y, Chou D.
    Neuropharmacology; 2019 Oct 01; 157():107667. PubMed ID: 31207251
    [Abstract] [Full Text] [Related]

  • 23. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
    Hashimoto K.
    Biochem Pharmacol; 2020 Jul 01; 177():113935. PubMed ID: 32224141
    [Abstract] [Full Text] [Related]

  • 24. (2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism.
    Riggs LM, Aracava Y, Zanos P, Fischell J, Albuquerque EX, Pereira EFR, Thompson SM, Gould TD.
    Neuropsychopharmacology; 2020 Jan 01; 45(2):426-436. PubMed ID: 31216563
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Ketamine increases vmPFC activity: Effects of (R)- and (S)-stereoisomers and (2R,6R)-hydroxynorketamine metabolite.
    Hare BD, Pothula S, DiLeone RJ, Duman RS.
    Neuropharmacology; 2020 Apr 01; 166():107947. PubMed ID: 31926944
    [Abstract] [Full Text] [Related]

  • 28. (2R,6R)-hydroxynorketamine rapidly potentiates optically-evoked Schaffer collateral synaptic activity.
    Riggs LM, Thompson SM, Gould TD.
    Neuropharmacology; 2022 Aug 15; 214():109153. PubMed ID: 35661657
    [Abstract] [Full Text] [Related]

  • 29. Mechanisms of ketamine action as an antidepressant.
    Zanos P, Gould TD.
    Mol Psychiatry; 2018 Apr 15; 23(4):801-811. PubMed ID: 29532791
    [Abstract] [Full Text] [Related]

  • 30. Antinociceptive and Analgesic Effects of (2R,6R)-Hydroxynorketamine.
    Yost JG, Wulf HA, Browne CA, Lucki I.
    J Pharmacol Exp Ther; 2022 Sep 15; 382(3):256-265. PubMed ID: 35779947
    [Abstract] [Full Text] [Related]

  • 31. IGF-1 release in the medial prefrontal cortex mediates the rapid and sustained antidepressant-like actions of ketamine.
    Deyama S, Kondo M, Shimada S, Kaneda K.
    Transl Psychiatry; 2022 May 17; 12(1):178. PubMed ID: 35577782
    [Abstract] [Full Text] [Related]

  • 32. Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine.
    Highland JN, Morris PJ, Zanos P, Lovett J, Ghosh S, Wang AQ, Zarate CA, Thomas CJ, Moaddel R, Gould TD.
    J Psychopharmacol; 2019 Jan 17; 33(1):12-24. PubMed ID: 30488740
    [Abstract] [Full Text] [Related]

  • 33. Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine.
    Chen BK, Luna VM, LaGamma CT, Xu X, Deng SX, Suckow RF, Cooper TB, Shah A, Brachman RA, Mendez-David I, David DJ, Gardier AM, Landry DW, Denny CA.
    Neuropsychopharmacology; 2020 Aug 17; 45(9):1545-1556. PubMed ID: 32417852
    [Abstract] [Full Text] [Related]

  • 34. Ketamine's antidepressant action: beyond NMDA receptor inhibition.
    Hashimoto K.
    Expert Opin Ther Targets; 2016 Nov 17; 20(11):1389-1392. PubMed ID: 27646666
    [Abstract] [Full Text] [Related]

  • 35. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.
    Pham TH, Gardier AM.
    Pharmacol Ther; 2019 Jul 17; 199():58-90. PubMed ID: 30851296
    [Abstract] [Full Text] [Related]

  • 36. Medial PFC AMPA receptor and BDNF signaling are required for the rapid and sustained antidepressant-like effects of 5-HT1A receptor stimulation.
    Fukumoto K, Fogaça MV, Liu RJ, Duman CH, Li XY, Chaki S, Duman RS.
    Neuropsychopharmacology; 2020 Sep 17; 45(10):1725-1734. PubMed ID: 32396921
    [Abstract] [Full Text] [Related]

  • 37. Ketamine metabolite (2R,6R)-hydroxynorketamine reverses behavioral despair produced by adolescent trauma.
    Elmer GI, Tapocik JD, Mayo CL, Zanos P, Gould TD.
    Pharmacol Biochem Behav; 2020 Sep 17; 196():172973. PubMed ID: 32569786
    [Abstract] [Full Text] [Related]

  • 38. (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice.
    Yamaguchi JI, Toki H, Qu Y, Yang C, Koike H, Hashimoto K, Mizuno-Yasuhira A, Chaki S.
    Neuropsychopharmacology; 2018 Aug 17; 43(9):1900-1907. PubMed ID: 29802366
    [Abstract] [Full Text] [Related]

  • 39. (2R,6R)-hydroxynorketamine improves PTSD-associated behaviors and structural plasticity via modulating BDNF-mTOR signaling in the nucleus accumbens.
    Gou L, Li Y, Liu S, Sang H, Lan J, Chen J, Wang L, Li C, Lian B, Zhang X, Sun H, Sun L.
    J Affect Disord; 2023 Aug 15; 335():129-140. PubMed ID: 37137411
    [Abstract] [Full Text] [Related]

  • 40. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites.
    Yang C, Yang J, Luo A, Hashimoto K.
    Transl Psychiatry; 2019 Nov 07; 9(1):280. PubMed ID: 31699965
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.